β-Blockers Are Effective in Congestive Heart Failure Patients With Atrial Fibrillation

Journal of Cardiac Failure

Volumn 9, Issue 5, 2003, Pages 398-403

  Meng, Fanbo ^a   Yoshikawa, Tsutomu ^a   Baba, Akiyasu ^b   Moritani, Kazunori ^c   Suzuki, Masahiro ^d   Satoh, Toru ^a   Yokozuka, Hitoshi ^e   Murayama, Akira ^f   Ogawa, Satoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO INSTITUTE HOSPITAL   (Japan)

^c Tachikawa Kyosai Hospital   (Japan)

^d SAITAMA NATIONAL HOSPITAL   (Japan)

^e ASHIKAGA RED CROSS HOSPITAL   (Japan)

^f Saitama Municipal Hospital   (Japan)

Author keywords

Brain natriuretic peptide; Carvedilol; Metoprolol; Norepinephrine

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; METOPROLOL;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM; TREATMENT PLANNING;

EID: 0242362771     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/S1071-9164(03)00127-1     Document Type: Article

References (21)

1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
2. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomized trial. Lancet 1999;353:9-13.
3. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Study Group. Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999;353:2001-7.
4. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
5. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. J Am Coll Cardiol 2001; 37:1692-9.
6. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Circulation 2002;106:2194-9.
7. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: V-HeFT Studies. Circulation 1993;87:VI-102-VI-110.
8. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. Circulation 1991;84:40-8.
9. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998:158:229-34.
10. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
11. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction. J Am Coll Cardiol 1998;32:695-703.
12. Yokota Y, Nomura H, Kawai H, Tsumura Y, Takeuchi Y, Kurozumi H, et al. Effects of long-term β-blockade (metoprolol) therapy in patients with dilated cardiomyopathy. Jpn Circ J 1991;55:343-55.
13. Hirooka K, Yasumura Y, Ishida Y, Hanatani A, Nakatani S, Komamura K, et al. Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy. Jpn Circ J 2001;65:931-6.
14. Yoshikawa T, Baba A, Suzuki M, Yokozuka H, Okada Y, Nagami K, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. Am J Cardiol 2000;85:1495-7.
15. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-adrenergic blocking agents. N Engl J Med 2002; 346:1357-65.
16. Lechat P, Hulot J, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001;103:1428-33.
17. Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC, Barbera SJ, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trial Program. Am Heart J 2001;142:498-501.
18. Fung JWH, Chan SKW, Yeung LYC, Sanderson JE. Is beta-blockade useful in heart failure patients with atrial fibrillation? Eur J Heart Failure 2002;4:489-94.
19. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. Comparative hemodynamic left ventricular functional and anti-adrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.
20. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002;105:2867-71.
21. Ohlstein EH, Atleth AJ, Storer B, Romanic AM. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol 1998;30:167-73.